2011 was a relatively light year for biotech M&A, but it looks like activity is picking up in 2012.
High levels of merger and acquisition activity will be the big theme of year for biotech, says Morningstar's Lauren Migliore.
Health-care analyst Lauren Migliore looks at what makes a biotech firm a likely takeout candidate and reveals our top five biotech M&A picks for 2010.
Gen-Probe's Michael Watts sees five potential new product launches as delivering top-line growth next year.
Some retirees qualify for up to six months of retroactive benefits; pay for those larger items
©2012 Morningstar Advisor. All right reserved.